New directions in the experimental therapy of tick-borne encephalitis

Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. There is no specific therapy for the treatment of TBE patients. However, several efforts are being made to develop small molecules that specifically interfere with the life cycle of TBE virus. In particular, recently various nucleoside analogues that can inhibit the viral replicase, such as the RNA-dependent RNA polymerase or viral methyl-transferases, have been explored. In addition, human or chimeric (i.e., structural chimeras that combine mouse variable domains with human constant domains) monoclonal antibodies with promising potential for post -exposure prophylaxis or early therapy have been developed. This review summarizes the latest directions and experimental approaches that may be used to combat TBE in humans.

Automated summary

Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. Currently, there is no specific therapy for TBE patients, but there are ongoing efforts to develop small molecules and monoclonal antibodies that can interfere with the TBE virus life cycle and potentially be used for post-exposure prophylaxis or early therapy. This review summarizes the latest directions and experimental approaches for combating TBE in humans.